News for Sinopharm Group Co., Ltd. (SHTDY)

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278 Partnership leverages strategic relationships to enable research and development of innovative treatments to advance Teva's Pivot to Growth strategy TEL AVIV, Israel and SHANGHAI, June 16, 2025 /PRNewswire/ -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ('Fosun Pharma', SSE: 600196, HKEX: 02196) today announced that the companies, through their respective subsidiaries, have entered a strategic partnership for the development of investigational TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy. Teva's internally developed ATTENUKINE technology provides a new mechanism of action, potentially offering high efficacy and low toxicity in a broad array of oncology indications.

Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY

PR NewswireITASCA, Ill., Nov. 25, 2024 ITASCA, Ill., Nov. 25, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a

ITASCA, Ill., Nov. 25, 2024 /PRNewswire/ -- Lakeside Holding Limited ('Lakeside' or the 'Company') (Nasdaq: LSH), a U.S.-based integrated cross-border supply chain solution provider with a strategic focus on the Asian market operating under the brand American Bear Logistics ('ABL'), announces that Hupan Pharmaceutical (Hubei) Co., Ltd. ('Hupan Pharmaceutical'), a company recently acquired by Lakeside, has established partnership with Sinopharm Group Hubei Co., Ltd. ('Sinopharm Hubei'). Sinopharm Hubei is a subsidiary of Sinopharm Group Co., Ltd., a leader in China's pharmaceutical industry. This partnership for essential medicine storage, transportation, and logistics services positions Lakeside for accelerated growth and solidifies its foothold in China's medical logistics sector.

Sinopharm Group's earnings quality is likely to be boosted by declining days sales outstanding. Learn why SHTDF stock is a Hold.

Acquisition Strengthens Lakeside's Pharmaceutical Logistics Capabilities in China, Projected to Add US$7 Million in Annual Revenue

Exploring the Dividend Sustainability and Growth Prospects of Sinopharm Group Co Ltd (SHTDF) Sinopharm Group Co Ltd (SHTDF) recently announced a dividend of $0.

Sinopharm Group (SHTDF) faces near-term challenges like declining drug prices and lower sales from hospitals. Check out why I rate the stock as a hold.

Visiongain has published a new report entitled Pharma Wholesale and Distribution Market Report 2024-2034: Forecasts by Type (Wholesalers (Producer...

Acumen Research and Consulting recently published report titled “Injectable Contraceptives Market Forecast, 2023 - 2032”...

SHANGHAI, Aug. 29, 2023 /PRNewswire/ -- On August 29, 2023, Shanghai Fosun Pharmaceutical Co., Ltd.* announced its 2023 Interim Results for the first half of 2023. . During the Reporting Period,...

/PRNewswire/ -- On August 29, 2023, Shanghai Fosun Pharmaceutical Co., Ltd.* (Stock Code: 600196.SH; 02196.HK) announced its 2023 Interim Results for the first...

DGS ETF has generated above-average yield and also steady capital gains over the long run. Read more to see my recommendation on the fund.

GuruFocus Article or News written by James Li and the topic is about: These stocks meet Buffett and Munger's key criteria

Visiongain has published a new report entitled Pharma Wholesale and Distribution 2022-2032. It includes profiles of Pharma Wholesale and Distribution and...

Visiongain has published a new report entitled Pharma Wholesale and Distribution 2022-2032. It includes profiles of Pharma Wholesale and Distribution...

Visiongain has published a new report entitled the Pharma Wholesale and Distribution Market Report 2021-2031. It includes profiles of Pharma Wholesale and...